Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bryostatin-1 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Neurotrope BioScience; Synaptogenix

    • Most Recent Events

    • 30 Jul 2021 Results of pooled analysis from NTRP101-202 and NTRP101-203, presented at the Alzheimer's Association International Conference 2021.
    • 22 Jan 2020 According to a Neurotrope BioScience media release, company is planning to meet with the Food and Drug Administration to present the totality of the clinical program data for Bryostatin-1 (NTRP101-202 and NTRP101-203).
    • 22 Jan 2020 According to a Neurotrope BioScience media release, Due to the baseline imbalance observed in the study, and because a clear signal of benefit could be observed in the raw data from the pre-specified Moderate Stratum, a post-hoc analysis using paired data for individual patients, with each patient as his/her own control has been conducted.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top